Klaus Schollmeier, PhD

Dr. Klaus Schollmeier is an advisor to the pharmaceutical/biotechnology industry. Dr. Schollmeier was Chief Executive Officer of SuppreMol in Munich from 2013 until 2015, when the company was sold to Baxalta. From 2004 to 2011, he served as Chief Executive Officer (CEO) of Santhera Pharmaceuticals in Basel and as chairman of the board of Santhera until 2013. Dr. Schollmeier joined Graffinity Pharmaceuticals AG in Heidelberg, Germany, as CEO in 2003 and merged the company with MyoContract AG, Basel, in 2004 to form Santhera. Prior to joining the biotechnology industry in 2003, he was Managing Director of the health care/biotechnology group at ING-BHF Bank for ING Group Europe. Before that, Dr. Schollmeier spent 16 years in the pharmaceutical industry at BASF, Knoll, and Abbott. He is a board member and chairman of several biotechnology companies, including Tacalyx (Germany), Modra Pharmaceuticals (The Netherlands), Affiris Pharma (Austria), and Eternygen (Germany).

Dr. Schollmeier holds a PhD in biology from the University of Düsseldorf, Germany, and is currently an Adjunct Research Associate Professor at the Boston University Medical School, Massachusetts.